M&T Bank Corp 4 D Molecular Therapeutics, Inc. Transaction History

M&T Bank Corp

$28.6 Billion
Q1 2024

A detailed history of M&T Bank Corp transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 29,343 shares of FDMT stock, worth $615,909. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,343

Previous 39,511 25.73%

Holding current value

$615,909

Previous $800,000 16.75%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$17.03 - $35.87 $173,161 - $364,726	-10,168 Reduced 25.73%	29,343 $934,000
Q4 2023 Feb 06, 2024	BUY	$9.76 - $21.25 $292 - $637	30 Added 0.08%	39,511 $800,000
Q3 2023 Nov 02, 2023	BUY	$12.64 - $19.76 $134,830 - $210,779	10,667 Added 37.02%	39,481 $502,000
Q1 2023 May 11, 2023	BUY	$15.45 - $23.19 $81,421 - $122,211	5,270 Added 22.38%	28,814 $495,000
Q4 2022 Feb 13, 2023	SELL	$6.85 - $25.46 $271,362 - $1.01 Million	-39,615 Reduced 68.0%	18,641 $414,000

Q4 2022 Feb 13, 2023	BUY	$6.85 - $25.46 $33,585 - $124,830	4,903 Added 26.3%	23,544 $522,000
Q3 2022 Nov 14, 2022	BUY	$6.96 - $11.48 $49,750 - $82,059	7,148 Added 13.99%	58,256 $468,000
Q2 2022 Aug 05, 2022	BUY	$5.68 - $15.99 $137,660 - $387,533	24,236 Added 90.19%	51,108 $356,000
Q1 2022 May 09, 2022	BUY	$13.16 - $22.64 $191,504 - $329,457	14,552 Added 118.12%	26,872 $406,000
Q4 2021 Feb 07, 2022	BUY	$19.56 - $32.94 $13,144 - $22,135	672 Added 5.77%	12,320 $270,000
Q3 2021 Oct 28, 2021	BUY	$22.73 - $36.04 $26,207 - $41,554	1,153 Added 10.99%	11,648 $314,000
Q4 2020 Feb 12, 2021	BUY	$38.43 - $47.36 $403,322 - $497,043	10,495 New	10,495 $435,000

Others Institutions Holding FDMT

# of Institutions

157

Shares Held

50.3M

Call Options Held

718K

Put Options Held

370K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $680M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account